Schiff Nutrition International Names Jennifer Steeves-Kiss Senior Vice President – Chief Marketing Officer
06 Julho 2011 - 5:05PM
Business Wire
Schiff Nutrition International, Inc. (NYSE: WNI) appointed
Jennifer Steeves-Kiss Senior Vice President – Chief Marketing
Officer, effective July 1, 2011.
Tarang Amin, president and chief executive officer of Schiff
Nutrition, stated, “We continue to implement our strategy to build
a world-class nutritional supplements company by strengthening the
leadership talent of our management team. As a key marketing
executive for almost two decades with Procter & Gamble
(P&G), Jennifer’s success in building premium brands and
leading innovation will be key assets to grow Schiff. We are very
excited to welcome Jennifer to our already strong management
team.”
“Schiff has leading brands in the growing nutritional
supplements industry and a solid platform for future growth,” said
Steeves-Kiss. “I look forward to helping the company expand its
brand management with new programs, including increased advertising
to drive growth.”
Steeves-Kiss, 39, has led consumer products marketing and brand
management teams for the past 17 years at P&G. Most recently
she was the Marketing Director for Always®, Whisper® brands and Fem
Care innovation. In this role, Steeves-Kiss established the global
team responsible for driving the $3 billion Always brand share
growth and led the Fem care innovation pipeline development. She
also held marketing leadership roles for the billion dollar
Charmin® and Bounty® businesses. She was also a key leader for
P&G FutureWorks, tasked with creating new brands and business
models for P&G. Steeves-Kiss started her career with P&G
Canada and holds a B.A. from Queen’s University, Kingston,
Ontario.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Move Free®, Schiff® Vitamins, MegaRed®, Mega-D3™ and
Tiger's Milk®. To learn more about Schiff, please visit the web
site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited
to: dependence on sales of our Move Free product and the joint
care category, dependence on sales of our MegaRed product,
dependence on individual customers, adverse publicity or consumer
perception regarding our nutritional supplements and/or their
ingredients, similar products distributed by other companies or the
nutritional supplement industry generally, the impact of
competitive products and pricing pressure (including expansion of
private label products), the inability to successfully bid on new
and existing private label business, the impact of raw material
pricing, availability and quality (particularly relating to joint
care products and ingredients from third-party suppliers outside
the United States, including China), claims that our products
infringe the intellectual property rights of others, the inability
to enforce or protect our intellectual property rights and
proprietary techniques against infringement, the inability to
successfully launch and maintain sales (especially in the joint
care and omega-3 categories) outside of the United States while
maintaining the integrity of the products sold and complying with
local regulations, the inability to appropriately respond to
changing consumer preferences and demand for new products, the
inability to gain or maintain market distribution for new products
or product enhancements including products in the probiotic space,
litigation and government or administrative regulatory action in
the United States and internationally, including FDA enforcement
and product liability claims, the inability or increased cost to
obtain sufficient levels of product liability and general
insurance, the inability to comply with existing or new
regulations, both in the United States and abroad, and adverse
actions regarding product formulation, claims or advertising,
product recalls or a significant amount of product returns,
dependence on a single manufacturing facility and potential
disruptions of our manufacturing operations, the inability to find
strategic transaction opportunities or the inability to
successfully consummate or integrate a strategic transaction
(including the inability to successfully integrate the assets
recently acquired from Ganeden), the inability to maintain or
attract key personnel, interruptions to our information technology
systems, control by our principal stockholders, and other factors
indicated from time to time in the company’s SEC reports, copies of
which are available upon request from the company’s investor
relations department or may be obtained at the SEC's web site
(www.sec.gov). These risks and
uncertainties should be carefully considered before making an
investment decision with respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024